The Roskamp Institute is pleased to announce that its second annual seminar, Grey Matters—A Symposium on Alzheimer’s Disease Research, is nearly sold out.

“We are thrilled with the outpouring of support for our Grey Matters event. The level of interest speaks to the fact that Alzheimer’s impacts so many people in so many ways,” said The Roskamp Institute CEO Fiona Crawford, Ph.D.

Current research from the Alzheimer’s Association found that one in nine people age 65 and older have Alzheimer’s dementia. By 2050, it is estimated that as many as 16 million Americans will have Alzheimer’s disease, with 135 million people affected worldwide—figures that do not take into account patients’ loved ones and caretakers. The emotional and financial costs of the disease are staggering.

Speakers at this interactive luncheon will present on a variety of topics concerning brain health, including potential treatments, lifestyle choices that help prevent degeneration, early symptom warnings, and clinical research updates.

This year’s featured speaker will be Andrew Keegan, M.D., Director of The Roskamp Institute Clinic. Key leadership from The Institute will also present the most recent Alzheimer’s research updates. Emily Walsh, publisher of Observer Media Group, will moderate the panel.

Funds raised from The Grey Matters Symposium provide direct monetary support to medical research currently conducted at The Roskamp Institute.

After establishing research facilities locally in 2003, the Roskamp Institute has made important discoveries with profound clinical implications for millions of Americans suffering from Alzheimer’s disease and other debilitating neurological disorders.

The Institute has become firmly established as a leading not-for-profit, independent body in the international research community with its programs and projects supported by the National Institutes of Health, the U.S. Department of Defense, the Veterans Administration, the European Commission Seventh Framework Programme, and several other national and international peer-reviewed agencies.

In addition to Alzheimer’s disease treatments, the Institute focuses on the development of new drugs and therapies to treat neurological disorders such as Traumatic Brain Injury, Gulf War Illness, Multiple Sclerosis, and other neuroinflammatory disorders.

For information on remaining sponsorships, please call Megan Micale at (941) 552-9832 or email [email protected]

Share This